All In Biotech

Drug Trial Radar · NCT06160895

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TQ-A3334 Tablet After Multiple Doses in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Dec 26, 2023

Primary completion

Jun 24, 2024

Study completion Aug 19, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects. The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.

Conditions

  • Hepatitis B

Interventions

  • TQ-A3334 tabletsDrug

    TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.

  • TQ-A3334 placebo tabletsDrug

    TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
  2. Severity of adverse events (AE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
  3. Incidence of serious adverse events (SAE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
  4. Severity of serious adverse events (SAE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
  5. Tolerability after drug administrationTime frame: From patient enrollment to withdrawal, estimated to be around 1 month.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.